In a regulatory filing, Apellis Pharmaceuticals director A. Sinclair Dunlop disclosed the sale of 24,000 common shares of the company on October 17 at a price of $49 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
- Apellis price target raised to $49 from $42 at Mizuho
- Goldman Sachs Says These 2 Healthcare Stocks Look Attractive — Here’s What Makes Them Each a ‘Buy’ Right Now
- Tesla initiated, Kellanova upgraded: Wall Street’s top analyst calls
- Goldman has ‘increasing comfort’ with Syfovre, starts Apellis at Buy
